Single-institutional experience of clinicopathological analysis and treatment for lung cancer patients with human immunodeficiency virus infection

Takahashi,Satoshi; Okuma,Yusuke; Watanabe,Kageaki; Hosomi,Yukio; Imamura,Akifumi; Okamura,Tatsuru; Gemma,Akihiko

doi:10.3892/mco.2017.1214

Single-institutional experience of clinicopathological analysis and treatment for lung cancer patients with human immunodeficiency virus infection

Authors:
- Satoshi Takahashi
- Yusuke Okuma
- Kageaki Watanabe
- Yukio Hosomi
- Akifumi Imamura
- Tatsuru Okamura
- Akihiko Gemma
View Affiliations

Affiliations: Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 113‑8677, Japan, Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 113‑8677, Japan, Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo 113‑8602, Japan
Published online on: April 6, 2017 https://doi.org/10.3892/mco.2017.1214
Pages: 765-769

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The advent of antiretroviral therapy has changed the disease spectrum constitution among patients living with human immunodeficiency virus (HIV), while the incidence of death due to non‑AIDS‑defining cancers, particularly lung cancer, continues to increase in the USA and Europe. However, the availability of detailed reports of the clinical characteristics of lung cancer among Asian populations is limited. The present study retrospectively analyzed the clinical characteristics, treatment regimens and outcomes of lung cancer patients with HIV who were treated in a single institution between 1988 and 2013. Of the 20 lung cancer patients living with HIV included in this study, 90% were diagnosed since 1996 in the post‑antiretroviral era. The median CD4+ cell count was 373.5/µl, whereas 65% of the patients were diagnosed with adenocarcinoma and 30% with squamous cell carcinoma. Epidermal growth factor receptor mutations were detected in 3 (27%) of the 11 specimens for which data were available, of which 65% had advanced‑stage disease. Of the 20 patients, 9 underwent surgery, 6 received radiotherapy and 5 received chemotherapy as a first‑line treatment. Treatment was generally well‑tolerated. The median survival period was 35.8 months for all stages and 14.0 months for advanced stages. The treatment outcomes in our institution were favorable in comparison with previous studies from the USA and Europe, although these findings may be due to ethnic differences or the efficacy of treatment for HIV and lung cancer.

View Figures

View References

1	UNAIDS: 2012 UNAIDS Report on the Global AIDS Epidemic. http://www.unaids.org/en/resources/publications/2012/name,76121,en.asp2012 Accessed. April 5–2017.
2	Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK and Wegner S: Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: A 20-year cohort study. AIDS. 23:41–50. 2009. View Article : Google Scholar : PubMed/NCBI
3	Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A and McKenna MT: Centers for Disease Control and Prevention (CDC): Revised surveillance case definitions for HIV infection among adults, adolescents and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. MMWR Recomm Rep. 57:1–12. 2008.PubMed/NCBI
4	Pakkala S and Ramalingam SS: Lung cancer in HIV-positive patients. J Thorac Oncol. 5:1864–1871. 2010. View Article : Google Scholar : PubMed/NCBI
5	Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM and Biggar RJ: HIV/AIDS Cancer Match Study: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 20:1645–1654. 2006. View Article : Google Scholar : PubMed/NCBI
6	Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI and Engels EA: Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 107:dju5032015. View Article : Google Scholar : PubMed/NCBI
7	Rengan R, Mitra N, Liao K, Armstrong K and Vachani A: Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: A population-based study. Lancet Oncol. 13:1203–1209. 2012. View Article : Google Scholar : PubMed/NCBI
8	Engsig FN, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J and Obel N: Lung cancer in HIV patients and their parents: A Danish cohort study. BMC Cancer. 11:2722011. View Article : Google Scholar : PubMed/NCBI
9	Clifford GM, Lise M, Franceschi S, Egger M, Bouchardy C, Korol D, Levi F, Ess S, Jundt G, Wandeler G, et al: Lung cancer in the Swiss HIV cohort study: Role of smoking, immunodeficiency and pulmonary infection. Br J Cancer. 106:447–452. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lanoy E, Spano JP, Bonnet F, Guiguet M, Boué F, Cadranel J, Carcelain G, Couderc LJ, Frange P, Girard PM, et al: The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. Int J Cancer. 129:467–475. 2011. View Article : Google Scholar : PubMed/NCBI
11	Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, et al: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer. 100:840–847. 2009. View Article : Google Scholar : PubMed/NCBI
12	Petoumenos K, Hui E, Kumarasamy N, Kerr SJ, Choi JY, Chen YM, Merati T, Zhang F, Lim PL, Sungkanuparph S, et al: Cancers in the TREAT Asia HIV observational database (TAHOD): A retrospective analysis of risk factors. J Int AIDS Soc. 13:512010. View Article : Google Scholar : PubMed/NCBI
13	Okuma Y, Tanuma J, Kamiryo H, Kojima Y, Yotsumoto M, Ajisawa A, Uehira T, Nagai H, Takeda Y, Setoguchi Y and Okada S: A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. J Cancer Res Clin Oncol. 141:1669–1678. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
15	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
16	HIV Classification: CDC and WHO Staging Systems. https://www.aidsetc.org/guide/hiv-classification-cdc-and-who-staging-systemsAccessed. November 23–2016.
17	The Japan lung cancer society: guideline for diagnosis and treatment of lung cancer 2015. https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3Accessed. November 23–2016.
18	Okuma Y, Yanagisawa N, Hosomi Y, Imamura A, Okamura T, Kato K and Negishi K: Concomitant chemoradiotherapy and antiretroviral therapy for HIV-infected patients with locoregionally advanced non-small cell lung cancer: Benefit and tolerability of treatment in 2 cases. Onkologie. 36:586–590. 2013. View Article : Google Scholar : PubMed/NCBI
19	Irwin LE, Begandy MK and Moore TM: Adenosquamous carcinoma of the lung and the acquired immunodeficiency syndrome. Ann Intern Med. 100:1581984. View Article : Google Scholar : PubMed/NCBI
20	Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD and Gazdar AF: Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA. 279:1554–1559. 1998. View Article : Google Scholar : PubMed/NCBI
21	Lavolé A, Chouaïd C, Baudrin L, Wislez M, Raguin G, Pialoux G, Girard PM, Milleron B and Cadranel J: Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer. 65:345–350. 2009. View Article : Google Scholar : PubMed/NCBI
22	White CS, Haramati LB, Elder KH, Karp J and Belani CP: Carcinoma of the lung in HIV-positive patients: Findings on chest radiographs and CT scans. AJR Am J Roentgenol. 164:593–597. 1995. View Article : Google Scholar : PubMed/NCBI
23	Grubb JR, Moorman AC, Baker RK and Masur H: The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS. 20:1095–1107. 2006. View Article : Google Scholar : PubMed/NCBI
24	Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, et al: A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 120:1194–1202. 2014. View Article : Google Scholar : PubMed/NCBI
25	Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, et al: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402. J Clin Oncol. 26:5401–5406. 2008. View Article : Google Scholar : PubMed/NCBI
26	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI